| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 12.125 | 31.676 | 29.605 | 7.910 | 17.043 | 5.238 |
| Total Income - EUR | - | - | - | - | 17.168 | 49.691 | 34.211 | 12.078 | 21.114 | 7.835 |
| Total Expenses - EUR | - | - | - | - | 6.341 | 37.893 | 25.467 | 25.766 | 22.003 | 10.353 |
| Gross Profit/Loss - EUR | - | - | - | - | 10.828 | 11.798 | 8.744 | -13.688 | -889 | -2.517 |
| Net Profit/Loss - EUR | - | - | - | - | 10.706 | 11.481 | 8.448 | -13.771 | -1.060 | -2.569 |
| Employees | - | - | - | - | 2 | 3 | 2 | 2 | 2 | 2 |
Check the financial reports for the company - Scandent Donto Lab S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 33.990 | 28.998 | 23.749 | 20.064 | 15.933 | 13.248 |
| Current Assets | - | - | - | - | 7.303 | 27.018 | 35.167 | 1.524 | 1.974 | 2.609 |
| Inventories | - | - | - | - | 0 | 3.682 | 3.601 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 2.777 | 0 | 108 | 0 | 1.645 | 828 |
| Cash | - | - | - | - | 4.526 | 23.335 | 31.458 | 1.524 | 329 | 1.781 |
| Shareholders Funds | - | - | - | - | 10.749 | 22.026 | 29.986 | -13.723 | -14.741 | -17.228 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 2.728 | 3.398 | 3.623 | 13.685 | 15.157 | 18.288 |
| Income in Advance | - | - | - | - | 27.817 | 30.591 | 25.307 | 21.627 | 17.491 | 14.797 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "3250 - 3250" | |||||||||
| CAEN Financial Year |
3250
|
|||||||||
Comments - Scandent Donto Lab S.r.l.